Author name: ClaritasRx

U.S. payers consider several factors when evaluating specialty therapies for coverage — all of which benefit from better data.

Third-party logistics providers can be a rich source of insight. Here are three things their data can help you understand.

Payers prefer to back data-based, evidence-driven therapies. Here’s the information they need to understand value.

Rare disease communities and their members offer a valuable source of qualitative data to other patients and healthcare providers.

Prior authorization can be improved by streamlining data collection and communication. Here’s how the Hub helps.

Key opinion leaders (KOLs) drive understanding and knowledge. Here’s how to connect with the top minds in rare diseases.

Data insights in specialty drug distribution drives better decision making. Here’s how the Hub provides key information.

Is your pharmaceutical market access strategy meeting its goals? Here’s what to track.

Complex U.S. payer systems in healthcare don’t lend themselves easily to economic models. Here’s how tech can help.

Which patients are at risk of stopping treatment during treatment and how can you intervene?